Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a promising new strategy to make cancer-fighting immune cells stronger and potentially longer-lasting, a discovery that could help improve the effectiveness of immunotherapies that use a patient's own immune…
Experts at the 2025 ICE-T Symposium reviewed CAR T-cell therapy, bispecific antibodies, and gene therapy across myeloma, lymphoma, autoimmune disease, and solid tumors, emphasizing safety and access. The analysis included 128 patients treated with BCMA-directed CAR T-cell therapy between December 2019 and December…
UC San Francisco scientists engineered B-SYNC CAR-T cells that activate only in the brain and cleared diffuse midline glioma in mouse models, with human trials planned as early as April 2027.
A new review synthesizes engineering strategies and early clinical findings for CAR-NK cell immunotherapy in blood cancers and solid tumors.
A conference correspondence summarizing 12 clinical and translational abstracts on next-generation CAR-T therapy for malignant brain tumors, reporting early feasibility alongside antigen loss and limited cell persistence. Chimeric antigen receptor T-cell therapy for malignant brain tumors is advancing rapidly, but the…
Scientists at UC San Francisco have engineered CAR-T cells that stay dormant until they reach the brain, where they switch on and destroy tumor cells. In mice, these CAR-T cells were able to clear diffuse midline glioma (DMG), a lethal…
Scientists at UC San Francisco have engineered CAR-T cells that stay dormant until they reach the brain, where they switch on and destroy tumor cells. In mice, these CAR-T cells were able to clear diffuse midline glioma (DMG), a lethal…
Octane Biotech Inc. (“Octane”) and Currus Biologics (“Currus”), an Australian biotech developing the BEAT, a proprietary, universal, bispecific antibody platform to unlock CAR T-cell therapy for solid... Octane Biotech and Currus Biologics Automate Manufacturing of CUR-001 CAR T-Cell Therapy on…
Sep 25, 2026, 10:54 ET At 2026 IMS: Updated FUMANBA-1 Data from IASO Bio's Equecabtagene Autoleucel (Fucaso) Demonstrate In Vivo Durable Persistence of CAR-T Cells Associated with Sustained MRD-Negativity and Delayed Disease Progression — Patients with del(17p), high tumor burden, and rapidly progressive disease were…
The Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) issued the clearance on October 1, 2026. The authorization covers protocol 7192, CARLLA-B1 — the first regulatory approval in Mexico's history for a clinical trial using chimeric antigen receptor T-cell (CAR-T) therapy produced domestically.
CAR-T, CAR-NK and TCR cell therapies for blood cancers, solid tumours and autoimmune disease: in-body CAR-T, off-the-shelf cells, new approvals and trials.
An article joins this feed when it matches these terms. Each one is also a search of its own.